IL10 and neoplasm: Studies have shown that the inhibition of Treg infiltration or the blocking of their key molecular products (e.g., CTLA-4 or IL-10) significantly enhances DC-mediated anti-tumor immune responses [46,47], confirming the suppressive effect of Tregs on DCs’ antigen-presenting capacity in TME.